GSK3B and Parkinson disease: Inhibition of GSK-3β can reduce the expression of α-synuclein and prevent cell death in cellular models of PD, suggesting that inhibiting GSK-3β may have neuroprotective effects on dopaminergic neurons by reducing the toxicity of α-synuclein overexpression.